Trillium Therapeutics Inc (TRIL) Noticias

TRIL I did not follow closely but great insight by you to invest in this CD-47 "player" (as hundreds of other strategies always compete for attention), and clearly closer causation my link yesterday pronounced:

"Turning off this pathway—a checkpoint interaction between a protein called SIRPa on the macrophage and the CD47 protein found on all 'self' cells—was the key to creating this therapy."

Been a wild ride. 20 cents to a buyout from Pfizer. Amazing.

Seeking alpha is reporting that the PFE buyout deal could close tonight.

https://seekingalpha.com/amp/news/3771497-trillium-therapeutics-gains-quickly-after-nasdaq-delisting-notice-on-pfizer-deal

TRIL rose 2.7% after a Nasdaq delisting notice indicated that the sale to Pfizer (NYSE:PFE) was tentatively scheduled to close prior to market open tomorrow. The stock is expected to be halted this evening, according to the notice. In late August Pfizer agreed to buy Trillium, a clinical stage immuno-oncology company, in a $2.3B deal. Under the terms of the agreement, Pfizer agreed to buy Trillium for an implied $18.50/share, in cash. The delisting notices comes as Trillium's HSR deadline for the Pfizer deal was scheduled to expire. Trillium didn't immediately return Seeking Alpha request for comment on the status of HSR. Last week, Trillium Therapeutics (TRIL) receives final court order approving arrangement.

From Seeking Alpha

TRIL has jumped from $18 to $18.45 today, which is close to the buyout price PFGE paid. No news has been issued but it looks liked the sale to PFE might be about to finalized. If so, the cash could be in our accounts before the end of 2021. I will enjoy paying capital gains on this massive windfall for me!

Thank you Leprecon777 that all makes sense then. I thought I wasn't seeing it right. Yeah an almost guaranteed 5% right? That's the way I was seeing it. I just wasn't sure and how long it would take.

I think I read somewhere where a investor called the Investor Relations Department and they stated it would be a couple more weeks before the documents are ready for distribution.

The stock price is sitting 5% below the buyout price to account for the small risk the deal falls through and to account for the time between now and the buyout.

I bought the stock after the buyout for the nearly guaranteed 5% return.

Ok so we sit and wait. When is the vote? I'm assuming we should have gotten some email or something then? I haven't gotten
Also makes me wonder why the price of this is sitting a $1 less than buyout price. I mean $1 of $17.50 is like 5%
Thanks for responding, my 1st buyout & I've been in stock market for less than 6 months. Yipeeee

99.99pct
Shareholders have to approve the buyout. But I have never seen a case where this has not occurred.

So is the buyout 100%? I own shares & I'm not sure if I'm supposed to do something or just wait?

Congrats. Tril holders.
Jim Cramer said yesterday that Pfizer has the money and he feels other buyouts cancel therapeutic research co.Co.
Adap.... has been moving past 2 days $4.38 if anyone wants to look into it.
Congrats to all
Parlee into adap

thisbguy got 1 lucky buyout now spreading think he know all

$TRIL Today Great news for $TRIL with the Buyout of Pfizer at $18,50. Big Profits.
I started buying TRIL at $0.285 August 22, 2019 and sold it in November 2020 at $20 in November 30, 2020.

Now is the time to think carefully about where to reinvest profits.
I strongly recommend that before investing, you can see OTLK you can see a lot of information about $OTLK at r/OTLK_Investors

My estimate for OTLK is that after BLA approval and start sales reach $25, with the possibility of a Buyout above $50

I reinvested my TRIL Profits on $OTLK (see r/OTLK Investors).
Same details about OTLK Wet AMD
Phase 3 have Great Results and safety.
U.S. FDA BLA submission targeted Q1-2022
BLA Approval 2Q-2022
Pre-commercialization activities underway .
Targeting $13.1 billion global ophthalmic anti-VEGF market.
12 years market exclusivity.
A Buyout to OTLK can happen anytime.
See also the OTLK Corporate Presentation
https://ir.outlooktherapeutics.com/static-files/046a3f66-c668-4bc3-a7c1-916236655b42

Thanks on this one Vinmantoo. Got in on your recommendation and averaged down to $7.50.

Corporalagarn (love that screen alias), great to hear you made out well. You are having a pretty damn good year with CDMO jumping so much too! If you are up for a bit more gambling, the other company I really love now is ENTA. DewDiligence, the guy who runs this board likes it a lot and knows more than I do.

Take care!

Thanks on this one Vinmantoo. Got in on your recommendation and averaged down to $7.50.

Congrats to all longs. I bought more shares as TRIL cratered to $6 and am at my peak # of TRIL shares now.

While I am happy at the quick price jump, I am a bit disappointed at the price. I was hoping a buyout would eventually come at a similar price as FTSV when they were bought by GILD. That would be $4.9 billion price, or more than twice the current buyout price. Still, a bird in the hand is worth 2 in the bush as there is no guarantee the phase 1/2 trials would show great results.

Now I can buy more ENTA!

While I think PFE got the company a bit too cheap, I'm not complaining.

This is dead now, ya? In terms of price movement. Won’t go past $18.50, if that.

Yeahhhhhhhh
Cam’on!
Now i can buy more TMDI!
Buahahahahhahahahahahahahahahahhahahahahahahhahahah

Just came. Hope you held

The company has dosed the first TP53-mutated AML patient with 622, in combination with azacitidine. In the trial, ~25 patients with newly diagnosed disease will be enrolled, with the primary endpoints of safety and CR rate.

they both are into oncology


BBBBbbbbbbwwwwwwwaaaaaa hhhhhhaaaaaa! Thanks for the laugh.

they both are into oncology

That has nothing to do with TRIL.

$TRIL or IBIO https://www.globenewswire.com/en/news-release/2021/07/08/2260252/0/en/iBio-Establishes-Oncology-Drug-Discovery-Pipeline-with-Three-New-Antibody-Programs.html

The company has dosed the first R/R AML patient with 622, in combination with azacitidine and venetoclax. This is being assessed as part of an ongoing, open-label trial. Around fifty elderly patients (at least 75 years old) or patients unfit for intensive induction chemo will be enrolled. The primary endpoints are safety and CR rate.

The company announces that it has dosed the first patient with 621, in combination with doxorubicin in a Phase I/II trial in leiomyosarcoma. It will enrol ~60 newly diagnosed patients, with primary endpoints being safety and ORR.

https://content.ftserussell.com/sites/default/files/russell_3000_index_additions_-_2021.pdf

PRs https://www.globenewswire.com/news-release/2021/04/28/2218460/33016/en/Trillium-Therapeutics-Provides-Data-Update-Announces-Phase-1b-2-Program-Priorities-Across-Hematologic-Malignancies-and-Solid-Tumors-and-Reports-Governance-Changes.html https://www.globenewswire.com/news-release/2021/04/28/2218489/0/en/Trillium-Therapeutics-Announces-Dosing-of-First-Patient-in-Phase-1b-Study-of-TTI-622-in-Combination-With-Carfilzomib-and-Dexamethasone-in-Relapsed-Refractory-Multiple-Myeloma.html

Slides https://s22.q4cdn.com/183592819/files/Trillium_RD-Day-2021_final_Updated.pdf

Link to the webcast https://event.on24.com/wcc/r/3129711/BFCFD551CEEF86B1D97BBE20BF99A46C

I expect this half the company to identify a RP2D for both. The current data support them potentially being best-in-class.

Laughing all the way to the bank. Good luck!!

Excellent to hear. Nothing wrong with cashing out with a nice profit. I sold 3% of my TRIL shares to recoup ~25% of my investment so I can't lose it all. Lots of upside still.

Laughing all the way to the bank. Good luck!!

TRIL has wasted too much time, even CRIS has developed a combo CA-4948 + ibrutinib to treat Relapsed or Refractory Hematologic Malignancies.
CD-47 space is a big leaking bubble.

Oh please, CRIS has dosed its first patient in phase 1. They aren't in phase 3. Your leaking bubble comment made me laugh. Thanks.

TRIL has wasted too much time, even CRIS has developed a combo CA-4948 + ibrutinib to treat Relapsed or Refractory Hematologic Malignancies.
CD-47 space is a big leaking bubble.

https://www.prnewswire.com/news-releases/curis-doses-first-patient-in-phase-1-study-of-ca-4948-in-combination-with-ibrutinib-in-patients-with-relapsed-or-refractory-hematologic-malignancies-301224625.html

This paper is a summary of 621 data that has already presented. It provides the justification of dose escalation beyond the 0.2 mg level. CD47 receptor occupancy was 34.4% at the 0.2 mg dosages, but jumped to 58.3%, 62.5% and 66.1% at 0.3mg, 0.4mg and 0.5mg, respectively https://clincancerres.aacrjournals.org/content/early/2021/02/19/1078-0432.CCR-20-3706

The trial is continuing with higher dosages.

On April 28, they plan to hold an R&D Day, at which they will:

Provide a data update for TTI-622 and TTI-621, including data for the 18 mg/kg and 2 mg/kg dose cohorts, respectively.

Announce key strategic priorities in terms of target indications and drug combinations across hematologic malignancies and solid tumours.

Outline clinical development plan and clinical studies to be initiated this year.

won't start unloading until a buyout comes this year or next.


$TRIL

If Gilead bought 47 last year for almost 5 billion.

I was in 47 from the low teens to the high 80's looking for a monster run in TRIL also 47 got bought out when they where in early phase 2 look for similar movement in the stock price for Trillium therapeutics in 2021.

https://www.gilead.com/news-and-press/press-room/press-releases/2020/3/gilead-to-acquire-forty-seven-for-49-billion


TRIL strong healthcare focused investor base. including strategic investment from Pfizer 292 million in cash...

Just joined the Trillium Board:
https://www.pfizer.com/people/medical-experts/oncology-cancer/jeff_settleman

https://trilliumtherapeutics.com/portfolio-item/jeff-settleman-phd/

added a few more shares before the new money comes in next week in 2021


Tril molecules are superior to 47 this has potential for exponential growth.

EMA cross on play and fibo levels key to watch a new uptrend with price going high and volume. thats a great sign.


new highs in 2021 looking for $60.00 target in 2021 & being bought out probably by Pfizer if you add up the investment & Jeff Settlemen addition to the TRIL board recently.

$TRIL

Added & bought some early calls 2021


$TRIL

TRIL Loaded 11.70's last week top monoclonal antibodies plays:

$TRIL
$HGEN


$TRIL

Looks like TTI-622 is reaching peak RO but TTI-621 isn't. That isn't so surprising given the lower doing of 621. The mean trough concentrations for both did increase at higher doses.

If CD47 is targeting M2, there should be some discussion of M2/M1 instead of T cell clones.

Looks like higher platelet depletion leads to higher ORR

This is a really nice thread comparing TRIL’s drugs to a competitor that got a big boost from some recently released data.

https://twitter.com/PersimmonTI/status/1335723469762416641

Dose Patients ORR
.1 mg/kg N=4 0%
.3 mg/kg N=4 0%
.8 mg/kg N=4 25%
2 mg/kg N=4 25%
4 mg/kg N=4 25%
8 mg/kg N=8 38%
12 mg/kg N=4 ?
18 mg/kg N=2 ?

ASH (622) presentation https://s22.q4cdn.com/183592819/files/ASH-2020-TTI-622-01-Poster-Presentation-FINAL.PDF

Did you count this Anti-CD47/PD-L1 Bispecific Antibody?

https://www.biospace.com/article/releases/innovent-announces-first-patient-dosed-in-the-phase-1-clinical-trial-of-anti-cd47-pd-l1-bispecific-antibody-in-china/

At least eight I know of, but based on the data so far TRIL likely has two best-in-class assets.

Yeah, but now TRIL has impressive data.